Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.49 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6646760 | 0.91 | KMT2A (0.67) | KMT2ATSHRAPEX1PKMNPC1 | |
| SCHEMBL6644972 | 0.90 | S1PR3 (0.53) | KMT2ATSHRS1PR3APEX1MAPT | |
| SCHEMBL30823673 | 0.88 | S1PR3 (0.54) | KMT2ATSHRS1PR3APEX1MAPT | |
| SCHEMBL20568042 | 0.88 | S1PR3 (0.54) | KMT2ATSHRS1PR3APEX1MAPT | |
| SCHEMBL6647212 | 0.87 | S1PR3 (0.53) | KMT2ATSHRS1PR3APEX1MAPT | |
| SCHEMBL7427480 | 0.86 | MAPT (0.66) | S1PR3APEX1PKMMAPTHSD17B10 | |
| SCHEMBL6196273 | 0.83 | KMT2A (0.56) | KMT2ATSHRS1PR3APEX1MAPT | |
| SCHEMBL20568064 | 0.83 | APEX1 (0.56) | KMT2ATSHRS1PR3APEX1NPC1 | |
| SCHEMBL30823654 | 0.83 | APEX1 (0.56) | KMT2ATSHRS1PR3APEX1NPC1 | |
| SCHEMBL31347917 | 0.81 | TSHR (0.57) | TSHRMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6916927-B2 | Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′-monophosphate phosphodiesterase (cGMP-PDE5) for the treatment of sexual dysfunction | PFIZER INC. | 2005-07-12 | — | — | US | disclosed |
| US-20040180944-A1 | Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP-PDE5) for the treatment of sexual dysfunction | PFIZER INC | 2004-09-16 | — | — | US | disclosed |
| EP-1257553-B1 | PYRROLOPYRIMIDINONE DERIVATIVES, PROCESS OF PREPARATION AND USE | SK CHEMICALS CO LTD (KR) | 2004-05-26 | — | — | EP | disclosed |
| US-6723719-B1 | DYSMENORRHOEA, BENIGN PROSTATIC HYPERPLASIA (BPH), BLADDER OUTLET OBSTRUCTION, INCONTINENCE, AGINA, CONGESTIVE HEART FAILURE, ATHEROSCLEROSIS; HYPOTENSIVE AND ANTIALLERGEN AGENTS | PFIZER INC | 2004-04-20 | — | — | US | disclosed |
| US-6642244-B2 | Sexual disorder therapy; cardiovascular disorders; antidiabetic agents; gastrointestinal disorders | BRISTOL-MYERS SQUIBB CO. | 2003-11-04 | — | — | US | disclosed |
| US-20020133008-A1 | Pyrazolopyridopyrimidine inhibitors of cGMP phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY | 2002-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180944-A1 | Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP-PDE5) for the treatment of sexual dysfunction | PDE5A, PDE3A, PDE3B | KMT2A 4191/4885TSHR 2600/4885S1PR3 893/4885 |
| US-20020133008-A1 | Pyrazolopyridopyrimidine inhibitors of cGMP phosphodiesterase | PDE5A, PDE3A, PDE2A | KMT2A 4447/4885TSHR 3557/4885S1PR3 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.